LCTC
Lifeloc Technologies, Inc.2.6000
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
7.16MP/E (TTM)
-Basic EPS (TTM)
-0.46Dividend Yield
0%Recent Filings
10-K
FY2025 results
Lifeloc posted FY2025 product sales of $8.96M, up 6% y/y from $8.47M, fueled by new customers and fleet refreshes—yet net loss swelled to $2.47M from $1.05M as R&D held steady at $2.15M while G&A climbed 11% on S-4 costs. Gross margins stuck at 40%, with core breathalyzer demand stable despite rental income vanishing post-June lease end. Cash dipped to $746K amid $354K SpinDetect capex, offset by $336K option exercises and $75K debenture; $1.1M mortgage and $825K debentures loom with 2030-31 maturities. SpinDetect betas kick off 2026. Quarterly results vary wildly. DOT approvals remain essential.
8-K
2025 results: revenue up, loss widens
Lifeloc Technologies reported 2025 revenue up 6% to $9.027 million, yet swung to a $2.470 million net loss from $1.053 million last year. The wider shortfall stemmed from a $1.738 million non-cash deferred tax valuation allowance hike. Gross margin held steady at 40.3%. SpinDetect drug analyzer nears commercialization with production mold underway Q1 2026.
10-Q
Q3 FY2025 results
Lifeloc posted Q3 revenue of $2.3M, up 8% y/y from $2.1M on stronger product sales, yet gross margin slipped to 40% from 44% amid inflation and tariffs. Operating loss widened to $234K from $208K as R&D dipped 12% to $459K but G&A jumped 26%; net loss hit $263K or $(0.10) per share, matching 2.75M diluted shares. Cash fell to $685K after $578K operating outflow, offset by $370K financing including debentures; term loan and $825K subordinated debentures (8.25%, maturing 2030) total ~$1.8M debt. Announced merger with ELST via stock exchange, pending approvals. Competition pressures pricing in breathalyzer markets.
8-K
Q3 revenue up, loss widens
Lifeloc Technologies reported Q3 2025 net revenue of $2.257 million, up 8% from $2.087 million last year, yet swung to a $263 thousand net loss from $158 thousand due to heavy R&D on SpinDetect drug analyzer. Gross margin slipped to 40.2% amid cost inflation and tariffs. Beta testing starts now; commercial launch eyed for 2026. Cash burn hurts.
8-K
Lifeloc inks ELST merger
Lifeloc Technologies signed a merger agreement on October 9, 2025, to acquire Electronic Systems Technology via a subsidiary merger, with ELST surviving as a wholly owned unit. ELST shareholders get Lifeloc common stock per a fixed exchange ratio, cash for fractions. Deal awaits shareholder nod, S-4 effectiveness, regulatory okay. Closing hinges on customs.
IPO
Website
Employees
Sector
Industry
A
Agilent Technologies, Inc.
139.19-1.41
AATC
Autoscope Technologies Corporat
6.18-0.01
BIAF
bioAffinity Technologies, Inc.
1.38-0.10
DHR
Danaher Corporation
224.70-3.83
LIQT
LiqTech International, Inc.
1.80-0.02
RSCF
Reflect Scientific, Inc.
0.05+0.00
SOBR
SOBR Safe, Inc.
1.44-0.06
TDY
Teledyne Technologies Incorpora
506.54-7.75
TRCK
Track Group, Inc.
0.30+0.00
WRAP
Wrap Technologies, Inc.
2.19-0.15